Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305394 | 0.81 | SMN1; SMN2 (0.44) | OPRM1 | |
| SCHEMBL28851436 | 0.78 | UBE2M (0.38) | — | |
| SCHEMBL707384 | 0.78 | SLC18A3 (0.38) | CCR5SLC6A3OPRM1 | |
| SCHEMBL1306676 | 0.78 | HRH3 (0.41) | OPRM1 | |
| SCHEMBL17095965 | 0.77 | OPRM1 (0.39) | CCR5SLC6A3OPRM1 | |
| SCHEMBL3839394 | 0.77 | TP53 (0.37) | CCR5SLC6A3OPRM1 | |
| SCHEMBL3888064 | 0.77 | GNAI3 (0.38) | CCR5SLC6A3OPRM1 | |
| SCHEMBL17095677 | 0.77 | OPRM1 (0.40) | CCR5OPRM1 | |
| SCHEMBL2523790 | 0.77 | CCR5 (0.37) | CCR5OPRM1 | |
| SCHEMBL2523794 | 0.77 | CCR5 (0.37) | CCR5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | CCR5 2739/4885SLC6A3 4368/4885OPRM1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.